世界の鎮痛剤(痛み止め)市場予測:麻薬性鎮痛薬/非麻酔鎮痛薬/神経因性疼痛薬/抗片頭痛薬/抗関節炎薬...市場調査レポートについてご紹介

【英文タイトル】PAIN RELIEVING DRUGS MARKET FORECAST 2014-2024
Future Prospects for Leading Companies

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Global Pain Relieving Drugs: Market Overview
1.2 Global Pain Relieving Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction to Pain and Pain Management
2.1 Pain: A Sensory And Emotional Phenomenon
2.1.1 Pain: A Short History
2.1.2 Pain Pathways And The Origin Of Pain
2.2 The World Health Organisation (WHO) Pain Ladder
2.2.1 Classification Of Pain
2.2.1.1 Acute Pain
2.2.1.2 Chronic Pain
2.3 The Psychosocial Effects Of Chronic Pain
2.3.1 Chronic Cancer Pain
2.3.2 Neuropathic Pain
2.3.3 Identifying Neuropathic Pain
2.4 The Neurochemistry Of Pain
2.4.1 Prostaglandins
2.4.2 Opioids
2.5 Pain Management – A Brief Overview
2.6 Pain Management Drugs
2.6.1 The Use Of Opioids In Pain Treatment
2.6.2 OTC Pain Relievers
2.7 Market Definition

3. World Pain Relieving Drugs Market 2014-2024
3.1 Global Pain Relieving Drugs: Market Overview
3.1.1 Categorisation of the Global Pain Relieving Drug Market
3.1.2 Pain Relieving Drugs: A Growing Market
3.2 The Global Pain Relieving Drugs Market in 2013
3.2.1 Market Dominance of Arthritic Pain Relieving Drugs
3.3 Global Pain Relieving Drugs: Market Forecast 2014-2024
3.3.1 Market Sectors That Will Drive Growth
3.3.2 Abuse Deterrents and Safety Measures Will Boost Narcotic Pain Relieving Drugs Market Growth
3.3.3 Changing Market Shares by Sector 2014-2024

4. Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024
4.1 The Global Narcotic Pain Relieving Drugs Market in 2013
4.1.1 Global Narcotic Pain Relieving Drugs: Market Forecast 2014-2024
4.1.2 Changing Market Shares By Leading Drugs 2014-2024
4.2 Opana ER (Endo Pharmaceuticals): Market Analysis
4.2.1 Tamper-Proof Opana ER Products
4.2.2 Opana ER: Historical Sales Analysis, 2014-2024
4.2.3 Opana ER: Sales Forecast 2014-2024
4.3 Duragesic: Market Analysis
4.3.1 Duragesic: Historical Sales Analysis, 2011-2013
4.3.2 Duragesic: Sales Forecast 2014-2024
4.4 Oxycontin ER: Market Analysis
4.4.1 Tamper Resistant Oxycontin ER
4.4.2 Oxycontin ER: Patent Expiries and Legal Battles
4.4.3 Oxycontin ER: Sales Forecast 2014-2024
4.5 Ultram: Market Analysis
4.5.1 Ultram: Sales Forecast 2014-2024
4.6 Zaldiar/Ixprim: Market Analysis
4.6.1 Zaldiar/Ixprim: Historical Sales Analysis, 2011-2013
4.6.2 Zaldiar/Ixprim: Sales Forecast 2014-2024
4.7 Other Narcotic Pain Relieving Drugs
4.7.1 Subsys (Insys Therapeutics)
4.7.2 Oxecta (Pfizer)
4.7.3 Other Narcotic Pain Relieving Drugs: Sales Forecast 2014-2024

5. Non-Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024
5.1 The Global Non-Narcotic Pain Relieving Drugs Market in 2013
5.1.1 Global Non-Narcotic Pain Relieving Drugs: Market Forecast 2014-2024
5.1.2 Changing Market Shares By Leading Drugs 2014-2024
5.2 Aspirin (Bayer): Market Analysis
5.2.1 Aspirin (Bayer): Historical Sales Analysis, 2010-2013
5.2.2 Aspirin (Bayer): Sales Forecast 2014-2024
5.3 Panadol: Market Analysis
5.3.1 Panadol: Historical Sales Analysis, 2008-2013
5.3.2 Panadol: Sales Forecast 2014-2024
5.4 Advil: Market Analysis
5.4.1 Advil: Historical Sales Analysis, 2012 and 2013
5.4.2 Advil: Sales Forecast 2014-2024
5.5 Tylenol: Market Analysis
5.5.1 Tylenol: Sales Forecast 2014-2024
5.6 Other Non-Narcotic Pain Drugs
5.6.1 Exparel (Pacira Pharmaceuticals)
5.6.2 Other Non-Narcotic Pain Drugs: Sales Forecast 2014-2024

6. Neuropathic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024
6.1 An Introduction to Neuropathic Pain
6.1.1 Identifying Neuropathic Pain
6.1.2 Pharmacological Interventions for Neuropathic Pain
6.1.2.1 Analgesics in Neuropathic Pain
6.1.2.2 Anti-Convulsants
6.1.2.3 Local Anaesthetics
6.1.2.4 Anti-Depressants
6.1.2.5 Aldose Reductase Inhibitors
6.1.3 The Global Neuropathic Pain Relieving Drugs Market in 2013
6.1.4 Global Neuropathic Pain Relieving Drugs: Market Forecast 2014-2024
6.1.5 Changing Market Shares By Leading Drugs 2014-2024
6.2 Lidoderm: Market Analysis
6.2.1 Lidoderm Patent Expiry and Endo Pharma – Watson/Actavis Agreement
6.2.2 Lidoderm Marketing Probe
6.2.3 Lidoderm: Historical Sales Analysis, 2009-2013
6.2.4 Lidoderm: Sales Forecast 2014-2024
6.3 Lyrica: Market Analysis
6.3.1 Lyrica: Historical Sales Analysis, 2009-2013
6.3.2 Lyrica: Sales Forecast 2014-2024
6.4 Cymbalta: Market Analysis
6.4.1 Cymbalta: Historical Sales Analysis, 2008-2013
6.4.2 Cymbalta: Sales Forecast 2014-2024
6.5 Neurontin: Market Analysis
6.5.1 Neurontin: Historical Sales Analysis, 2009-2013
6.5.2 Neurontin: Sales Forecast 2014-2024
6.6 Nucynta: Market Analysis
6.6.1 Nucynta: Historical Sales Analysis, 2011-2013
6.6.2 Nucynta: Sales Forecast 2014-2024
6.7 Other Neuropathic Pain Relieving Drugs
6.7.1 Retigabine (GSK; Valeant)
6.7.2 Other Neuropathic Pain Relieving Drugs: Sales Forecast 2014-2024

7. Anti-Migraine Drugs: World Market Analysis and Forecast 2014-2024
7.1 Migraine: An Introduction
7.1.1 Management of Migraine
7.1.2 Drugs Being Used In the Treatment of Migraine
7.1.3 Other Migraine Relieving Techniques
7.1.4 The Global Anti-Migraine Pain Relieving Drugs Market in 2013
7.1.5 Global Anti-Migraine Pain Relieving Drugs: Market Forecast 2014-2024
7.1.6 Changing Market Shares By Leading Drugs 2014-2024
7.2 Relpax: Market Analysis
7.2.1 Relpax: Historical Sales Analysis, 2009-2013
7.2.2 Relpax: Sales Forecast 2014-2024
7.3 Maxalt: Market Analysis
7.3.1 Maxalt: Historical Sales Analysis, 2008-2013
7.3.2 Maxalt: Sales Forecast 2014-2024
7.4 Imitrex/Imigran: Market Analysis
7.4.1 Imitrex/Imigran: Historical Sales Analysis, 2008-2013
7.4.2 Imitrex/Imigran: Sales Forecast 2014-2024
7.5 Zomig: Market Analysis
7.5.1 Zomig: Licensing Transfers and Exclusivity
7.5.2 Zomig: Historical Sales Analysis, 2009-2013
7.5.3 Zomig: Sales Forecast 2014-2024
7.6 Botox (Allergan): Market Analysis
7.6.1 Botox: Historical Sales Analysis, 2009-2013
7.6.2 Botox: Sales Forecast 2014-2024
7.7 Treximet: Market Analysis
7.7.1 Treximet: Agreements Between GSK, Pozen Pharmaceuticals and Pernix Therapeutics
7.7.2 The Generic Treats to Treximet
7.7.3 Treximet: Historical Sales Analysis, 2008-2013
7.7.4 Treximet: Sales Forecast 2014-2024
7.8 Axert: Market Analysis
7.8.1 Axert: Historical Sales Analysis, 2011-2013
7.8.2 Axert: Sales Forecast 2014-2024
7.9 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast, 2014-2024
7.10 Anti-Migraine Pain Relieving Drugs Market – Future Prospects
7.10.1 Unmet Needs in the Treatment of Migraine

8. Anti-Arthritic Pain Drugs: World Market Analysis and Forecast 2014-2024
8.1 Understanding Arthritis: An Introduction to its Aetiology and Prevalence
8.1.1 Management of Arthritic Conditions
8.1.2 Drugs Being Used In The Treatment Of Arthritis
8.1.2.1 Analgesics As Pain Relieving Drugs
8.1.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
8.1.2.3 Corticosteroids
8.1.2.4 Disease Modifying Anti-Rheumatic Drugs (DMARDS)
8.1.3 Biological Drugs in the Treatment Of Arthritis
8.1.3.1 Biologics Used for Rheumatoid Arthritis
8.1.3.2 The Potential Side Effects of Biologics in the Treatment of Arthritis
8.1.4 The Global Anti-Arthritis Pain Relieving Drugs Market in 2013
8.1.5 Global Anti-Arthritis Pain Relieving Drugs: Market Forecast 2014-2024
8.1.6 Changing Market Shares By Leading Drugs, 2014-2024
8.2 Humira: Market Analysis
8.2.1 Humira: Historical Sales Analysis, 2011-2013
8.2.2 Humira: Sales Forecast 2014-2024
8.3 Enbrel: Market Analysis
8.3.1 Enbrel: Co-Promotions and Marketing Rights
8.3.2 Enbrel: Historical Sales Analysis, 2008-2013
8.3.3 Enbrel: Patent Expiries and Potential Competition, 2014-2024
8.3.4 Enbrel: Sales Forecast 2014-2024
8.4 Remicade: Market Analysis
8.4.1 Remicade: Historical Sales Analysis, 2008-2013
8.4.2 Remicade: Patent Expiries and Potential Competition, 2014-2024
8.4.3 Remicade: Sales Forecast 2014-2024
8.5 Voltaren: Market Analysis
8.5.1 Voltaren: Historical Sales Analysis, 2008-2013
8.5.2 Voltaren: Sales Forecast 2014-2024
8.6 Rituxan (Rituximab, MabThera): Market Analysis
8.6.1 Rituxan: Historical Sales Analysis, 2008-2013
8.6.2 Rituxan: Patent Expiries and Potential Competition, 2014-2024
8.6.3 Rituxan: Sales Forecast 2014-2024
8.7 Celebrex: Market Analysis
8.7.1 Celebrex: Historical Sales Analysis, 2008-2013
8.7.2 Celebrex: Patents, Exclusivity, and Competition, 2014-2024
8.7.3 Celebrex: Sales Forecast 2014-2024
8.8 Arcoxia: Market Analysis
8.8.1 Arcoxia: Historical Sales Analysis, 2008-2013
8.8.2 Arcoxia: Sales Forecast 2014-2024
8.9 Other Anti-Arthritis Pain Relieving Drugs
8.9.1 Duexa (Horizon Pharma)
8.9.2 Lodotra/RAYOS (Horizon Pharma; SkyePharma)
8.9.3 Ofatumumab (Genmab, GSK)
8.9.4 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast 2014-2024
8.10 Anti-Arthritic Pain Relieving Drug Market – Future Prospects

9. Leading National Markets for Pain Relieving Drugs 2014-2024
9.1 The Pain Relieving Drug Market By Region
9.1.1 The Global Distribution of Pain Relieving Drugs In 2013
9.2 Leading National Markets: Forecast, 2014-2024
9.2.1 Changing Market Shares By Region, 2014-2024
9.3 Regional Pain Relieving Drugs Markets: Analysis and Forecasts, 2014-2024
9.4 United States: The Largest Pain Relieving Drug Market
9.5 The EU5 Markets
9.5.1 EU5 Markets: Changing Market Shares by Country, 2014-2024
9.5.2 Germany
9.5.3 UK
9.5.4 France
9.5.5 Italy
9.5.6 Spain
9.6 Japan
9.7 China
9.8 South Korea
9.9 Brazil
9.10 India
9.11 Russia
9.12 Turkey
9.13 Rest of the World

10. Pain Relieving Drugs: R&D Pipeline 2014-2024
10.1 Innovative Products Currently In Development Will Drive Growth
10.1.1 Large Developmental Pipelines Encouraged By High Potential Growth
10.2 Development Pipeline For Narcotic Pain Relieving Drugs, 2014
10.2.1 Remoxy (Durect, Pain Therapeutics, Pfizer)
10.2.2 MoxDuo IR (Shire; China Aoxing; QRxPharma)
10.2.3 ALO-02 (Pfizer)
10.2.4 DETERx – COL-003 (Collegium Pharmaceuticals)
10.2.5 Acurox (Acura; Pfizer)
10.2.6 Morphine-6-Glucuronide (Paion)
10.2.7 Acuracet (Acura)
10.2.8 ARX-02 (AcelRx Pharmaceuticals)
10.2.9 Zohydro ER (Zogenix)
10.2.10 BEMA Buprenorphine (BioDelivery Sciences; Endo Pharmaceuticals)
10.3 Development Pipeline For Non-Narcotic Pain Relieving Drugs, 2014
10.3.1 Lofexidine Hydrochloride (US World Meds)
10.3.2 Synera (Nuvo Research)
10.3.3 Neosaxitoxin (Proteus SA; Boston Children Hospital)
10.3.4 OMS103 (Omeros)
10.3.5 Tetrodotoxin (CK Life Sciences; WEX Pharmaceuticals)
10.4 Development Pipeline For Neuropathic Pain Relieving Drugs, 2014
10.4.1 Perampanel (Eisai)
10.4.2 Serenbotase (Syntaxin, Ipsen, Allergan)
10.4.3 EMA401 (Spinifex Pharmaceuticals)
10.4.4 Ralfinamide (Newron)
10.4.5 NT-11624 (Neurotune)
10.4.6 AmiKet (Immune Pharmaceuticals)
10.4.7 Eladur (Durect; Impax Laboratories)
10.4.8 Clonidine Gel (Arcion Therapeutics; BioDelivery Sciences)
10.4.9 AVP-923 (Avanir Pharmaceuticals)
10.4.10 ARC-2022 (Arcion Therapeutics)
10.5 Development Pipeline For Anti-Migraine Pain Relieving Drugs, 2014
10.5.1 Zecuity (NuPathe; Teva)
10.5.2 Lasmiditan (CoLucid Pharmaceuticals)
10.5.3 NXN-188 (NeurAxon)
10.5.4 Levadex/Semprana (Allergan)
10.6 Development Pipeline For Anti-Arthritis Pain Relieving Drugs, 2014
10.6.1 Zavryl/Ibuprofen-PC (PLx Pharma)
10.6.2 Naproxcinod (NicOx)
10.6.3 Xeljanz (Pfizer)
10.6.4 Masitinib (AB Science)
10.6.5 Belimumab (GSK, Human Genome Sciences)
10.7 What Does the Future Hold for Pain Relieving Drugs Research and Development?
10.8 Solubility: A Hindrance To Drug Development
10.9 Monoclonal Antibodies (MAbs) – Potential Novel Pain Drugs Facing Challenges
10.10 New Opioids Providing Opportunities For Growth
10.11 The Potential Use Of Cannabinoids In Pain Relief

11. Qualitative Analysis for the Global Pain Relieving Drugs Market 2014-2024
11.1 Market Factors Influencing The Pain Relieving Drugs Market
11.2 SWOT Analysis Of The Pain Relieving Drugs Market, 2014-2024
11.2.1 Strengths
11.2.1.1 Cost Effectiveness: A Major Driver for Growth
11.2.1.2 Promising Candidates In The R&D Pipeline
11.2.2 Weaknesses
11.2.2.1 Product Withdrawals And Slow Regulatory Approvals
11.2.2.2 Concerns Over Drug Side Effects
11.2.2.3 Education In Pain Management Is A Key Unmet Need
11.2.3 Opportunities
11.2.3.1 Reformulations Of Existing Drugs Will Drive Market Growth
11.2.3.2 Reforms In Narcotics Offer Growth Opportunities
11.2.3.3 Ageing Population – Growth Driver For Pain Relieving Drugs
11.2.3.4 The Economic Benefits Of Expansion Into Emerging Markets
11.2.3.5 OTC Switching May Help To Delay Generic Erosion
11.2.4 Threats
11.2.4.1 Patent Expiries Will Lead To Generic Competition
11.2.4.2 Regulatory And Pricing Scrutiny Could Suffocate Market Growth
11.2.4.3 Inadequate Reimbursement Levels: A Potential Restraint On Market Growth
11.3 STEP Analysis Of The Pain Relieving Drugs Market, 2014-2024
11.3.1 Social Factors Affecting The Pain Relieving Drugs Market
11.3.2 Technological Factors Affecting the Pain Relieving Drugs Market
11.3.3 Economic Factors Affecting The Pain Relieving Drugs Market
11.3.4 Political Factors Affecting The Pain Relieving Drugs Market

12. Expert Opinions
12.1 Interview With Dr Stephen K Doberstein, Senior Vice President And Chief Scientific Officer, Nektar Therapeutics
12.1.1 Pain Relieving Drugs: Current Trends In The Market
12.1.2 Nektar’s NKTR-181 Product And Its Mechanism To Mitigate Against Opioid Abuse
12.1.3 Key Developments In Pain Management And The Steps Being Taken To Reduce Addiction To Pain Drugs
12.1.4 Nektar’s Development Programme And Issues Around Penetration Of The Blood-Brain Barrier
12.1.5 Future Expansion Plans
12.1.6 On The Unmet Need For Abuse-Resistant And Highly Efficacious Pain Relieving Drugs
12.1.7 On The Developments Expected To Enter The Market In The Coming Years And The Need To Re-invent Known Classes Of Analgesic Molecules
12.2 Interview With Dr Tom McCarthy, Chief Executive Officer, Spinifex Pharmaceuticals
12.2.1 The Quest For Alternative Pain Relief Therapies
12.2.2 The Future Potential Of Combination Therapies In Pain Relief
12.2.3 On Developing, Validating and Demonstrating The Clinical Potential Of Novel Mechanisms For Tackling Pain
12.2.4 On The Market Potential Of Spinifex’s EMA401 Product
12.2.5 On Expansion Plans For EMA401 And Pain Relief As A Whole
12.2.6 The Drug Development And Commercialisation Challenges Facing The Pain Relieving Drugs Market
12.2.7 Future Outlook On The Market And The Potential For Novel Analgesics

13. Conclusions
13.1 Market Overview
13.2 The Likely Impacts Of Patent And Exclusivity Expiries On Pain Relieving Drugs
13.3 Major Growth Drivers For Pain Relieving Drugs
13.4 Under-Served Needs In Neuropathic Pain Leaves Room For Growth
13.5 The Narcotic Pain Relieving Drugs Market: Its Driving And Restraining Factors
13.6 Botox Approval Expected To Boost Anti-Migraine Submarket
13.7 The Rise Of Biological Anti-Arthritic Pain Drugs
13.8 Emerging Markets Set To Drive Steer Market Forward
13.9 What Does The Future Hold For Pain Relieving Drugs?


【レポート販売概要】

■ タイトル:世界の鎮痛剤(痛み止め)市場予測:麻薬性鎮痛薬/非麻酔鎮痛薬/神経因性疼痛薬/抗片頭痛薬/抗関節炎薬
■ 英文:PAIN RELIEVING DRUGS MARKET FORECAST 2014-2024
Future Prospects for Leading Companies
■ 発行日:2014年9月
■ 調査会社:visiongain
■ 商品コード:VISG409041
■ 調査対象地域:グローバル
  • 世界のメチシリン耐性黄色ブドウ球菌(MRSA)治療薬市場動向(2012-2016)
    TechNavio's analysts forecast the Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market to grow at a CAGR of 3 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in prevalence of the MRSA infection. The Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market has also been witnessing the increase in Government …
  • 尋常性ざ瘡(Acne Vulgaris):グローバル製薬市場機会分析と予測
    OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018 Summary Despite its considerable patient population, the acne market has been overlooked and remained stagnant for the last decade. There has been a lack of research efforts due to the perception of a poor return on investment for topical treatments, the mainstay of acne therapy. There is an array of treatment options …
  • 神経性無食欲症(Anorexia Nervosa):世界の治験レビュー(2015年上半期版)
    Anorexia Nervosa Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Anorexia Nervosa Global Clinical Trials Review, H1, 2015" provides data on the Anorexia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment statu …
  • ベビー用電子玩具の世界市場2015-2019
    About Baby Electronic Toys Toys and games are used for the amusement and entertainment of children. Activity toys such as building sets, dolls, puzzles, and card games help children enhance their mental agility, and develop coordination and dexterity. These are considered as recreational items that not only keep the kids engaged, but also train them. Different materials are used to manufacture toy …
  • グローバルパッケージング産業の景況感レポート(2015年上半期)
    Summary “Packaging Business Confidence Report H1 2015” is a new report by Canadean that globally analyzes industry opinions on the latest economic and consumer issues, and their impact on investment decisions and growth prospects within the packaging industry. This report also examines executive opinion about the current and future state of the economy, and its retrospective effect on the industry …
  • インドの乳製品市場動向(~2022)
    Indian Dairy Industry holds an inimitable space in the country for its high employment potential and for ensuring the availability of nutritious yet affordable food for India’s ever increasing population. Getting the tag of largest milk producer was made possible by Operation Flood and the historic dairy cooperative movement; and as production increased, dairy industry started showing promising gr …
  • 世界の無線ネットワークインフラ市場(2014 – 2020)
    The term “Wireless Network Infrastructure” has conventionally been associated with macrocell Radio Access Network (RAN) and mobile core network infrastructure, which SNS Research estimates to account for nearly $52 Billion in spending by the end of 2014. However, the scope of the term is expanding as wireless carriers increase their investments in Heterogeneous Network or HetNet infrastructure enc …
  • 殺ダニ剤の世界市場:作物タイプ別(果物・野菜、シリアル・穀類、油糧種子・豆類)、適用法別(葉面散布、土壌処理)、由来別(生物学的、化学的)、形態別(乾燥剤、液体)、地域別予測
    Global Miticides Market to reach USD 1.70 billion by 2025. Global Miticides Market valued approximately USD 1.0 billion in 2016 is anticipated to grow with a healthy growth rate of more than 6.0% over the forecast period 2017-2025. Miticides are crop protection chemicals that specifically target plant mites. They constitute an important group of crop protection chemicals used to protect plants fro …
  • HMIソフトウェアの世界市場
    About HMI SoftwareHMI software is used to control the operation of a plant and this helps in improving the efficiency of the factory. This software aids in providing real-time data and data logging that are used in analytics to make strategic decisions. Technavio’s analysts forecast the global HMI software market to grow at a CAGR of 5.27 % during the period 2017-2021. [Covered in this report] The …
  • コートジボワールの通信、モバイル、ブロードバンド市場
    Executive summary VipNet prepares for commercial LTE launch, offering competition to Orange This report provides a comprehensive overview of trends and developments in Cote d’Ivoire’s telecommunications market. Subjects covered include: The impact of the recent political and economic crisis; Key statistics; Market and industry overviews; Government policies affecting the telecoms industry; Market …
  • PT(プロトロンビン時間)検査市場:米国、ヨーロッパ、日本
    The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and PT testing specifically, will become more standardized, offering opportun …
  • 電気自動車用充電器の世界市場:AC充電器、DC充電器、ワイヤレス充電器
    About Electric Vehicle Charger An electric vehicle charging station (EVCS) supplies the electricity required to recharge batteries in electric vehicles. EVCS are also called electric vehicle charging stations/systems, electric vehicle supply equipment (EVSE), and electric charging points. Various modes of charging are available, including home chargers, commercial/public charging stations, and wor …
  • 風力タービン Rotor Blades-世界市場規模、価格、競争環境、主要地域分析(~2020)
    Wind Turbine Rotor Blades - Global Market Size, Average Price, Competitive Landscape and Key Country Analysis to 2020 Summary “Wind Turbine Rotor Blades - Global Market Size, Average Price, Competitive Landscape and Key Country Analysis to 2020” is the latest report from industry analysis specialist GlobalData, offering comprehensive information and analysis of the global wind rotor blade market. …
  • モバイル決済の世界市場2015-2019
    About mobile payment Mobile payment is a form of payment where an end-user can initiate a transaction using a mobile device for goods and services through communication networks or technologies. Mobile payment allows consumers to use a mobile device to pay for goods and services instead of using cash, check, and credit/debit cards. It is also referred to as mobile money, mobile money transfer, and …
  • マイクロプログラマブルロジックコントローラー(PLC)の世界市場予測・分析2020-2024
    Global Micro Programmable Logic Controller (PLC) Market: About this market Technavio’s micro programmable logic controller (PLC) market analysis considers sales from the automotive industry, oil and gas industry, water and wastewater industry, power industry, food and beverage industry, and other end-users. Our study also finds the sales of micro PLC in APAC, Europe, MEA, North America, and South …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。